1. Home
  2. PBYI vs HCVI Comparison

PBYI vs HCVI Comparison

Compare PBYI & HCVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • HCVI
  • Stock Information
  • Founded
  • PBYI 2010
  • HCVI 2021
  • Country
  • PBYI United States
  • HCVI United States
  • Employees
  • PBYI N/A
  • HCVI N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • HCVI Blank Checks
  • Sector
  • PBYI Health Care
  • HCVI Finance
  • Exchange
  • PBYI Nasdaq
  • HCVI Nasdaq
  • Market Cap
  • PBYI 176.1M
  • HCVI 176.6M
  • IPO Year
  • PBYI N/A
  • HCVI 2021
  • Fundamental
  • Price
  • PBYI $2.56
  • HCVI $10.69
  • Analyst Decision
  • PBYI Strong Buy
  • HCVI
  • Analyst Count
  • PBYI 1
  • HCVI 0
  • Target Price
  • PBYI $7.00
  • HCVI N/A
  • AVG Volume (30 Days)
  • PBYI 338.9K
  • HCVI 52.6K
  • Earning Date
  • PBYI 10-31-2024
  • HCVI 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • HCVI N/A
  • EPS Growth
  • PBYI N/A
  • HCVI N/A
  • EPS
  • PBYI 0.18
  • HCVI N/A
  • Revenue
  • PBYI $219,143,000.00
  • HCVI N/A
  • Revenue This Year
  • PBYI N/A
  • HCVI N/A
  • Revenue Next Year
  • PBYI N/A
  • HCVI N/A
  • P/E Ratio
  • PBYI $14.09
  • HCVI N/A
  • Revenue Growth
  • PBYI N/A
  • HCVI N/A
  • 52 Week Low
  • PBYI $2.13
  • HCVI $10.30
  • 52 Week High
  • PBYI $7.73
  • HCVI $11.47
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 45.60
  • HCVI 66.57
  • Support Level
  • PBYI $2.48
  • HCVI $10.62
  • Resistance Level
  • PBYI $2.64
  • HCVI $10.68
  • Average True Range (ATR)
  • PBYI 0.14
  • HCVI 0.01
  • MACD
  • PBYI 0.06
  • HCVI 0.00
  • Stochastic Oscillator
  • PBYI 80.49
  • HCVI 100.00

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About HCVI Hennessy Capital Investment Corp. VI

Hennessy Capital Investment Corp VI is a shell company.

Share on Social Networks: